An injectable hydrogel “drug reservoir” device was created to deliver CD47 antibodies and macrophage-targeted altered nanocarriers (pCAR-NPs) in a “filled form” to the postoperative tumor cavity of GBM. This evidence concerns the gene CD47 and neoplasm.